Sorafenib is a potent multikinase inhibitor that targets the Raf/MEK/ERK pathway, as well as VEGFR1/2/3, PDGFR-β, KIT, Flt-3, and RET,[11] and has been approved in several countries worldwide for the treatment of renal cell carcinoma and HCC.[10], [13] In the SHARP study, sorafenib was both effective and safe in patients with advanced HCC,[10], [11], [12] but Child–Pugh liver function class B or C was an exclusion criterion.[10] Importantly, this classification does not evaluate the severity of portal hypertension, but reflects the extent of biological and clinical complications of cirrhosis. The gene discussed is FLT3; the disease is portal hypertension.